Sleep deprived healthy adults
Conditions
Interventions
1. Study setting
The study (behavioral and EEG tests) will be conducted in the Clinical Neurophysiology and Cognitive Neuroscience (CLINCON) laboratory at the Department of Physiology, Faculty of Med
and the second participant is given placebo first and the active treatment second and so on. L-theanine-caffeine combination and placebo will be administered on 2 separate days (one week apart) in a
Sponsors
Faculty of Medicine, University of Peradeniya.
Eligibility
Inclusion criteria
Inclusion criteria: The participants will be, sleep-deprived healthy young adults between the age of 20-30 years recruited from the community, both male and female.The participants in this study will be acutely sleep-deprived overnight before the day of the testing. The day before testing they will only have a post-lunch siesta for 2 hours. (Further details about sleep deprivation and the test preparation protocol are given in the attached protocol).
Exclusion criteria
Exclusion criteria: All individuals meeting any of the exclusion criteria at baseline will be excluded from study participation 1. Gross impairment of vision or hearing that would prevent the participants from performing neuropsychological tasks 2. Inability to read and follow written instructions 3. The participants who consume more than 5 cups of tea, coffee, or other caffeinated drinks per day.(Assessed by a qualified doctor in a detailed clinical interview conducted with the potential participants). 4. Who have alcohol dependence or abuse (Assessed by a qualified doctor in a detailed clinical interview conducted with the potential participants). 5. Who smoke or consume nicotine in any form. (Assessed by a qualified doctor in a detailed clinical interview conducted with the potential participants). 6. Who use recreational psychoactive drugs 7.Who have any longstanding illnesses like epilepsy, strokes, and any other neurological or psychiatric illnesses and have taken treatment for such illnesses 8. Who have a previous history of head trauma 9. Who have undergone a stressful or traumatic experience in the recent past.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Selective visual attention is the primary cognitive domain examined in the proposed experimental study. It will be evaluated by using a visual oddball paradigm. Visual stimuli will be presented, and the reactions will be recorded using the Presentation® (Neurobehavioral Systems, Inc. Albany CA) software on a Windows TM-based personal computer. At the end of the test neurobehavioral measures are recorded in the computer. Difference between active treatment and placebo in the pre-postdose changes (i.e., pre-postdose difference with active treatment minus pre-postdose difference with placebo) of following measures in the visual selective attention task: Neurobehavioral measures: 1.1.Number of hits (correct responses to targets) 1.2.Number of false alarms (active responses made for safe scenes) 1.3.Reaction time to the target stimuli [Pre-dose test before the administration of the active treatment/placebo and post-dose test 45 minutes after the administration of the treatment / placebo.] A BioSemi Active Two EEG/ERP acquisition system with ActiView software (BioSemi, Amsterdam) will be used to acquire EEG data. Continuous EEG data will be acquired from a 32-channel electrode cap configured to international 10–20 scalp electrode placement standards. Cognitive event-related potentials (ERPs) are derived from the EEG data. ERPs waveforms are neurophysiological measures of attentive processing (P300 component) and pre-attentive processing (N1 component). Neurophysiological measures: 2.1. Latency of P300 ERP component (this corresponds to speed of attentive processing in the brain) 2.2. Amplitude of P300 ERP component (this corresponds to the amount of neural resources allocated of attentive processing of the brain) 2.3. Latency of N1 ERP component (this corresponds to the speed of pre-attentive processing of the brain) 2.4. Amplitude of N1 ERP component (this corresponds to the amount of neural resources allocated for pre-attentive processing of the brain [Pre-dose | — |
Secondary
| Measure | Time frame |
|---|---|
| None [] | — |
Countries
Sri Lanka
Contacts
Public ContactProf. Tharaka Dassanayake
Professor in Neurophysiology
Outcome results
None listed